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Abstract: Genetically engineered neural stem cell (NSC) transplants offer a key strategy to 
augment neural repair by releasing therapeutic biomolecules into injury sites. Genetic 
modification of NSCs is heavily reliant on viral vectors but cytotoxic effects have prompted 
development of non-viral alternatives, such as magnetic nanoparticle (MNPs). NSCs are 
propagated in laboratories as either 3-D suspension “neurospheres” or 2-D adherent 
“monolayers”. MNPs deployed with oscillating magnetic fields (“magnetofection technology”) 
mediate effective gene transfer to neurospheres but the efficacy of this approach for 
monolayers is unknown. It is important to address this issue as oscillating magnetic fields 
dramatically enhance MNP-based transfection in transplant cells (e.g., astrocytes and 
oligodendrocyte precursors) propagated as monolayers. We report for the first time that 
oscillating magnetic fields enhanced MNP-based transfection with reporter and functional 
(basic fibroblast growth factor; FGF2) genes in monolayer cultures yielding high 
transfection versus neurospheres. Transfected NSCs showed high viability and could re-form 
neurospheres, which is important as neurospheres yield higher post-transplantation viability 
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versus monolayer cells. Our results demonstrate that the combination of oscillating magnetic 
fields and a monolayer format yields the highest efficacy for MNP-mediated gene transfer 
to NSCs, offering a viable non-viral alternative for genetic modification of this important 
neural cell transplant population. 
Keywords: nanoparticle; magnetofection; neural cell; stem cell; transplantation; genetic 
engineering 
 
1. Introduction 
Multipotent neural precursor/stem cells (NSCs) derived from the developing/adult central nervous 
system (CNS) or embryonic stem cells are a major transplant population, offering benefits of  
self-renewal and multipotentiality for cell replacement. Clinical transplantation trials of human fetal 
NSCs have been initiated including for Pelizaeus-Merzbacher disease, chronic spinal cord injury, 
amyotrophic lateral sclerosis, stroke, Batten’s disease (a lysosomal storage disorder) and Parkinson’s 
disease, with some successful outcomes [1–5]. Apart from cell replacement, NSCs are believed to 
mediate pro-regenerative mechanisms, including neurotrophic support, scavenging of toxic molecules, 
immunomodulatory activity and suppression of scarring reactions in injury sites (reviewed by [2]). 
Further, these cells show low immunogenicity, are non-tumorigenic [2] (unlike embryonic stem cells [6] 
and induced-pluripotent stem cells [7]) and can functionally integrate into the host neural circuitry. 
Notably, NSCs can migrate long distances, especially towards foci of pathology (termed 'pathotropism'), 
of relevance for repair of large or multifocal lesions [8]. This migratory capacity, coupled with their 
amenability to genetic engineering makes NSCs ideal cellular “vehicles” for delivery of therapeutic 
molecules (e.g., neurotrophins) to injury sites [9].  
Genetic modification of NSCs is heavily reliant currently on viral vectors [10,11] but instances of 
cytotoxicity and altered cell physiology have been reported [12–15]. Additionally, requirements for 
costly infrastructure for large-scale virus production means there is a significant “barrier to translation” 
for therapies using virally transduced NSCs, prompting a major drive for the development of non-viral 
vector systems [16,17]. Magnetic nanoparticles (MNPs) [18–23] are advanced materials comprising 
magnetic cores overcoated with biocompatible polymers that bind/condense DNA [21,24] and have emerged 
as an important class of non-viral gene delivery agents in recent years. Application of static/oscillating 
magnetic fields can dramatically enhance MNP based gene delivery (the so called “magnetofection” 
method) [18,19,22,23] and as gene transfer relies on intrinsic cellular endocytotic mechanisms, this 
approach shows high safety versus techniques such as nucleofection and electroporation [15,25,26].  
In experimental neurology, NSCs are propagated using two major culture formats—namely 
“neurospheres” and “monolayers”—with distinct features. We recently proved that application of 
oscillating magnetofection technology could enhance MNP-based transfection of NSCs propagated as 
neurospheres [23] but the method has never been tested for NSC monolayers. This is an important issue 
to address as oscillating magnetofection methods can significantly improve gene delivery to adherent 
cultures of neural cells such as astrocytes [19] and oligodendrocyte precursor cells (OPCs) [18]. The 
optimal frequencies showed cell type dependence (4 Hz for OPCs and 1 Hz for astrocytes); additionally, 
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the major differences between neural cells in terms of nanoparticle uptake and handling [27] means that 
data from one neural cell type cannot be extrapolated to another, so that NSC monolayers warrant 
independent investigation. Therefore, the aims of this study were to investigate: (i) the effects of static 
and oscillating magnetic fields on MNP based delivery of reporter genes (single and combinatorial gene 
transfer) to NSC monolayers; (ii) the survival of magnetofected NSCs and their ability to form 
neurospheres (i.e., the optimal culture format for cell transplantation procedures) to evaluate procedural 
safety; and (iii) the potential of the optimized protocol for functional gene delivery. 
2. Results and Discussion 
2.1. MNP-Mediated Gene Delivery to NSCs: Effect of Static and Oscillating Magnetic Fields 
Healthy monolayer cultures of NSCs were routinely derived from dissociated neurospheres, 
predominantly comprising cells with elongated cell bodies with two or more processes (Figure 1A).  
In preliminary transfection experiments (n = 2 cultures) using Neuromag at 2 µL/well or 6.9 µL/mL 
culture medium (i.e., a concentration recommended by Oz Biosciences for neuronal transfection), 
marked toxicity was observed in monolayers with an applied static magnetic field, evidenced by reduced 
cell adherence and rounding at 48 h (data not shown); this was not apparent in the absence of a magnetic 
field. Under an applied static magnetic field, negligible cytotoxicity was observed when the Neuromag 
dose was reduced to 0.62 µL/well or 2.1 µL/mL culture medium (data not shown). As procedural safety 
was of paramount concern in these experiments (to develop a method that is suitable for clinical 
translation), the latter dose was employed in all further monolayer experiments. For the same reason, a 
positive control, for example, a common non-viral procedure such as nucleofection was not studied here 
as this can result in significant loss of cell viability despite high transfection efficiency [15].  
Basal GFP expression was detected in NSC monolayers with no applied field (Figure 1B) with a 
significant increase on magnetic field application (Figure 1C). In the absence of applied fields, mean 
transfection efficiency was 9.4% which almost doubled to 18.4% with application of a static field  
(Figure 1D). Oscillating fields of varying frequencies (0.5–4 Hz) also stimulated gene delivery, and the 
effects were frequency-dependent (Figure 1D). An oscillating field of F = 4 Hz yielded the highest mean 
transfection efficiency of 32.2% (Figure 1D), significantly higher than that obtained using static fields. 
The protocol established here is a technically simple, rapid and single step procedure, compared to 
the multifection protocols that are required to achieve similar transfection levels in suspension cultures 
of NSCs [20]. Furthermore, the transfection efficiency reported here with the oscillating field of F = 4 Hz 
is three-fold that of neurospheres magnetofected under the same field conditions [23]. Magnetofection 
enhances transfection by increasing particle sedimentation and particle contact with cells [21]. Monolayers 
offer specific physical advantages over neurospheres in this context being relatively “two dimensional” 
and adherent rather than free-floating. The first attribute allows particle access to all cells in the system, 
whereas neurospheres may have inaccessible cells in their centres, reducing transfection efficiencies. 
This concept is supported by a decline in the extent of transfection of neurospheres with increased time 
in culture pre-transfection (and hence greater neurosphere diameter) [20]. The second attribute is 
important as the applied field source is more likely to increase particle-cell interactions in adherent cells 
than in suspension cell systems as field strength diminishes with increasing distance from the magnet.  
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Figure 1. Effect of magnetofection with static (F = 0 Hz) and oscillating (F = 0.5–4 Hz) 
magnetic fields on transfection efficiency. (A) Representative phase image of monolayer 
cultures; (B) Representative double-merged image of DAPI-stained cultures at 48 h after 
Neuromag-mediated transfection with pmaxGFP conducted in the absence of a magnetic 
field; (C) Representative double-merged image of DAPI-stained cultures at 48 h after 
Neuromag-mediated transfection with pmaxGFP with an applied oscillating magnetic field 
of F = 4 Hz; (D) Bar chart showing proportions of transfected cells in NSC monolayers at 
48 h after addition of Neuromag and pmaxGFP complexes with application of the indicated 
magnetic field.*P < 0.05 & ***P < 0.001 versus no magnetic field; +++P < 0.001 versus static 
(F = 0 Hz) magnetic field; n = 4 cultures (one-way ANOVA and Bonferroni’s MCT). Scale 
bar = 200 µm in (A, B & C). 
An optimal oscillation frequency of 4 Hz was established for NSC monolayers, however the 
mechanism/s by which oscillating magnetic fields enhance transfection, and the reasons for cell type-specific 
differences in optimal oscillation frequencies [18,19,23] are currently unknown. Oscillating magnetic 
fields may impart a lateral movement to particles, increasing their dispersion, as well as act to sediment 
particles. This may influence particle-plasmid complex uptake directly, by modulating the interaction of 
complexes with the cellular uptake machinery, and/or indirectly, via mechanical stimulation of cells, 
altering intrinsic endocytotic activity. In the former scenario, the rate at which coated pit formation  
(for receptor-mediated endocytosis) or membrane ruffling (for macropinocytosis) occurs, for example, 
may determine the frequency-dependence of a particular cell type, whereas in the latter scenario, factors 
such as cell-specific differences in the expression of mechanoreceptors, cell size or cell rigidity may be 
important. Nevertheless, further work is required to more fully investigate the mechanism of action of 
magnetic oscillation.  
In order to examine long term gene expression with this procedure, neurospheres were formed from 
transfected cells at 48 h post-transfection, and these were passaged at weekly intervals. At 7 days in vitro 
(9 days post-transfection) for the “no field” condition, around one third of neurospheres demonstrated 
J. Funct. Biomater. 2015, 6 263 
 
 
GFP expression, but this was confined to a minor proportion of cells within spheres (Table 1). Higher 
proportions of GFP expressing spheres were apparent for the field-conditions, which displayed more 
extensive GFP expression (Table 1). Further passage revealed a marked decline in the proportions of 
labelled spheres after 7 days in culture (i.e., at 16 days post-transfection) for all magnetic field 
conditions, with the extent of cell labelling within spheres classified as exclusively “low” (Table 1). 
Negligible GFP expression was observed after one further passage. Thus the methodology results in 
transient gene expression [up to 14 days; such transient expression is likely to be beneficial for conditions 
where repair is regulated by dynamic, temporally controlled molecular expression patterns (e.g., multiple 
sclerosis or spinal cord injury)]. For conditions where prolonged expression of therapeutic factors is 
required, it should be possible to achieve stable gene expression in NSCs by magnetofection, for 
example, by using plasmids that confer neomycin resistance coupled with antibiotic selection [15].  
Table 1. Long-term GFP expression in neurospheres derived from transfected monolayers. 
Monolayers were transfected with pmaxGFP with the indicated applied magnetic fields. At 
48 h, cells were detached and passaged as neurospheres; spheres were dissociated and  
re-plated at weekly intervals. At the indicated times, the proportion of GFP expressing 
neurospheres and the extent of GFP expression (based on the proportion of cells within a 
sphere demonstrating GFP expression) were scored; categories for the latter were “low” 
(≤10% cells), “moderate” (11%–50% cells) and “high” (≥51% cells).  
Days in vitro Field GFP+ spheres (%) 
Extent of GFP expression (% GFP+ spheres) 
Low Medium High 
7 
(n = 4) 
None 33.2 ± 3.0 95.5 ± 2.7 4.5 ± 2.7 0.0 
F = 0 Hz 57.7 ± 7.2 a 89.1 ± 7.3 6.3 ± 3.6 4.9 ± 4.5 
F = 4 Hz 69.8 ± 1.6 c 76.3 ± 11.0 16.0 ± 5.0 7.8 ± 6.9 
14 
(n = 3) 
None 3.6 ± 0.6 100.0 0.0 0.0 
F = 0 Hz 9.6 ± 1.4 a 100.0 0.0 0.0 
F = 4 Hz 13.4 ± 2.3 b 100.0 0.0 0.0 
a P < 0.05; b P < 0.01; and c P < 0.001 versus no magnetic field (one-way ANOVA and Bonferroni’s MCT). 
2.2. Safety of MNP-Mediated Gene Delivery 
Assessment of the safety of the developed protocols was limited to three magnetic field conditions: 
(i) no field, yielding the lowest transfection efficiency; (ii) static field (F = 0 Hz), currently the most 
widely used method for magnetofection; and (iii) oscillating field of F = 4 Hz, yielding the highest 
transfection efficiency. Compared with plasmid only controls, Neuromag-pmaxGFP complex addition 
had no effect on total cell number (Figure 2A) or viability (Figure 2B) at 48 h, irrespective of the 
magnetic field condition. For more stringent examination of toxicity, a neurosphere formation assay was 
employed in which the ability of transfected cells to form neurospheres was tested at 48 h post-transfection, 
with neurospheres allowed to form for 7 days. This biological assay allows for functional evaluation of 
cell stemness/proliferative capacity, which is key to the regenerative capacity of a transplant population 
such as the NSCs. Cells from treated cultures formed neurospheres (Figure 2C), which appeared 
morphologically similar to those from control cultures (Figure 2C, inset) with extensive GFP expression 
in neurospheres from transfected cultures (Figure 2D). Neurosphere number (Figure 2E) and size  
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(Figure 2F) were similar between control and treated samples under all magnetic field conditions, 
indicating that the transfection protocols had no adverse effects on NSC self-renewal. In all experiments, 
the applied magnetic fields per se had no effect on cell number or viability (Figure 2A,B) or neurosphere 
formation (Figure 2E,F). 
 
Figure 2. Effects of transfection protocols on cell viability and neurosphere formation. 
Monolayers (n = 4 cultures) were transfected with Neuromag-pmaxGFP complexes or with 
pmaxGFP only for controls, with application of the indicated magnetic fields. After 48 h, 
cells were detached from wells and a small proportion stained with trypan blue. (A) Bar chart 
showing the total number of cells per well. (B) Bar chart showing the proportion of viable 
cells. (C) Representative phase-contrast image of neurospheres formed from monolayers 
treated with particle/plasmid complexes; inset shows neurospheres formed from monolayers 
treated with plasmid only. (D) Fluorescence micrograph of neurospheres shown in (C), 
demonstrating GFP expression at 9 days post-transfection. (E) Bar chart showing the average 
sphere number per microscopic field. (F) Bar chart showing the average sphere diameter. 
Scale bar = 100 µm in (C,D). 
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The high safety of the methods is likely to be related to the fact that cells rely on intrinsic endocytotic 
mechanisms for MNP uptake. From a clinical perspective, the high viability of magnetofected cells is 
significant, since there is a need to avoid procedures which exacerbate underlying host pathology, 
including the transplantation of dead or dying cells which can result in further activation of host immune 
responses. The ability of transfected cells to reform neurospheres is also significant in this respect, since 
the survival of NSCs post-transplantation may be improved by the grafting of neurospheres rather than 
dissociated NSCs, due in part to increased cell-to-cell survival signalling and reduced anoikis in the 
neurosphere transplant population [28–30]. Thus, oscillating field magnetofection of monolayer cultures 
followed by neurosphere formation (as demonstrated here for the first time), may offer the best approach 
for the transplantation of NSCs genetically engineered by non-viral methods, since it has the potential 
to ensure both high gene delivery efficacy and optimal graft survival. 
2.3. MNP-Mediated Combinatorial Gene Delivery 
Given the complex nature of neural pathologies, it is unlikely that delivery of a single gene will be 
sufficient to augment regenerative processes in areas of neural injury, consequently combinatorial gene 
delivery was assessed here to more rigorously assess the clinical translational potential of the developed 
protocol. In co-transfected cultures, expression of both RFP and GFP could be clearly observed  
(Figure 3A main image and insets), with the majority of transfected cells expressing both reporter 
proteins. In all cases, co-transfected cells expressed normal cellular and nuclear morphologies with no 
evidence of cell rounding or loss, suggesting that combinatorial delivery is safe. On average, 87% of 
transfected cells expressed RFP plus GFP, whilst 11% expressed GFP only and the remaining 2% 
expressed RFP only (Figure 3B). These findings were in accordance with the results of the single plasmid 
transfection controls, which demonstrated a tendency (P = 0.056; paired Students t-test; n = 3 cultures) 
towards a lower transfection efficacy for the RFP-encoding plasmid versus the GFP-encoding plasmid 
(21.5% ± 1.9% versus 29.3% ± 2.8%) (Figure 3C). This is in accordance with the observation that 
transfection efficiency declines with increasing plasmid size (see Section 2.4), since the RFP-encoding 
plasmid is larger than the GFP-encoding plasmid (4.6 kb versus 3.5 kb). 
Therefore, the transfection procedures are applicable to combinatorial gene delivery, of relevance for 
a delivery of a “biomolecule cocktail” to enhance distinct aspects of neural regeneration such as blood 
vessel and axonal outgrowth, highlighting the versatility of the methods. Combinatorial gene delivery 
was achieved in a high proportion (87%) of transfected cells by simply mixing the two plasmids in equal 
proportions before adding to particles; the relative expression levels of exogenous genes in transplant 
populations could therefore be fine-tuned by simply varying the proportions of plasmids used. This 
strategy is especially pertinent when the therapeutic aim requires the combinatorial delivery of several 
factors with differing potencies in host tissue.  
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Figure 3. MNP–mediated combinatorial gene delivery to NSC monolayers. Cultures (n = 3) 
were magnetofected (oscillating magnetic field of F = 4 Hz) with complexes formed between 
Neuromag MNPs and either pDRE2, pmaxGFP or pDRE2 plus pmaxGFP (1:1 mix) 
plasmids; in all transfections, the final concentration of each plasmid was half that employed 
in the standard protocol. (A) Representative image of cells co-transfected with both 
plasmids. (A, insets) same field of cells in (A), showing GFP or RFP expression alone at  
48 h post-transfection; (B) Bar chart showing the proportions of transfected cells that express 
GFP plus RFP, GFP alone and RFP alone after co-transfection of plasmids; (C) Bar chart 
showing transfection efficiencies for co-transfection and the corresponding single gene 
transfection controls. Scale bar = 20 µm in (A–C). 
2.4. MNP-Mediated Functional Gene Delivery 
Cells which had been transfected with pFGF2-GFP displayed a characteristic pattern of predominantly 
nuclear GFP expression (Figure 4A; main image) irrespective of the magnetic field condition. This 
contrasted with the more extensive cellular distribution of GFP after transfection with either pAN-GFP 
(Figure 4A inset) or pmaxGFP (e.g., see Figure 1B). The application of magnetic fields enhanced the 
transfection of all three plasmids; an oscillating field of 4 Hz yielded higher transfection efficiencies 
than a static field in all cases (Figure 4B). However, under each magnetic field condition, the proportions 
of GFP-expressing cells were lower after transfection with either pFGF2-GFP or pAN-GFP than with 
pmaxGFP. Notably, transfection efficiency was inversely related to plasmid size for all magnetic fields 
(Figure 4C).  
Immunoblotting of cell extracts with a FGF2 antibody revealed the presence of a unique band of  
60 kDa in cells transfected with pFGF2-GFP when compared with cells transfected with pAN-GFP 
(Figure 4D); since the GFP tag contributes 26 kDa, the unique product corresponds to a FGF2 isoform 
of 34 kDa. The low abundance of this unique species relative to other endogenous FGF2 isoforms 
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common to cells transfected with pAN-GFP and pFGF2-GFP plasmids (Figure 4D) is consistent with 
the restraints that plasmid size places on overall gene delivery efficacy (Figure 4C), with only a minor 
proportion of cells (between 4.1% and 13.5%; depending on magnetic field condition) achieving 
successful transgene (FGF2-GFP) transfection. 
 
Figure 4. MNP-mediated delivery of a functional gene encoding FGF2—effect of 
magnetofection on transfection efficiency. Monolayers (n = 3 cultures) were transfected with 
Neuromag complexed with either pFGF2-GFP, pAN-GFP (control plasmid lacking the 
FGF2 insert) or pmaxGFP (positive control), with application of the indicated magnetic 
fields, then studied at 48 h post-transfection. (A) Representative phase and fluorescence 
double-merged image of cells transfected with pFGF2-GFP, demonstrating nuclear 
expression of GFP. Inset is a representative image of cells transfected with pAN-GFP; note 
that GFP expression extends throughout the cytoplasm. (B) Bar chart showing the 
proportions of transfected NSCs under no magnetic field (none), static magnetic field (F0) 
and oscillating magnetic field (F = 4 Hz; F4) conditions. *P < 0.05 and ***P < 0.001 for 
inter-field comparisons (indicated at top of chart) for a given plasmid; +++P < 0.001 versus 
pmaxGFP for a given magnetic field condition (one-way ANOVA and Bonferroni’s MCT); 
n = 3 cultures. (C) Regression analysis demonstrating transfection efficiency is inversely 
related to plasmid size under no magnetic field (None; r2 = 0.994; P < 0.05), static magnetic 
field (F0; r2 = 0.998; P < 0.05) and oscillating (F = 4 Hz) magnetic field (F4; r2 = 0.999;  
P < 0.01) conditions. (D) Immunoblots sequentially probed with antibodies to FGF2 (top) 
and β-actin (loading control; bottom), demonstrating expression of a 60 kDa protein species 
(indicated by arrow) in extracts of cells (n = 3 cultures) transfected with pFGF2-GFP  
(lanes 2, 4 and 6) but not with pAN-GFP (lanes 1, 3 and 5); the migration of size markers is 
displayed on the right-hand side. Scale bar = 5 µm in (A).  
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In agreement with earlier findings, for all three plasmids, microscopy revealed no obvious adverse 
effects on cell morphology and cell adherence for cells treated with complexes compared with cells 
treated with plasmid alone. Further analysis of cells transfected under oscillating (F = 4 Hz) magnetic 
field conditions, i.e., conditions which yield the highest transfection efficiencies, revealed normal total 
counts and cell viability at 48 h after delivery of either pFGF2-GFP or pAN-GFP (Figure 5A,B), 
consistent with findings for pmaxGFP. 
 
Figure 5. Magnetofection of a plasmid encoding FGF2 has no effect on cell viability and 
stimulates cell proliferation in the absence of exogenous FGF2. Monolayers (n = 3 cultures) 
were transfected with Neuromag complexed with either pFGF2-GFP or pAN-GFP (control 
plasmid), with application of an oscillating (F = 4 Hz) magnetic field. At 48 h post-transfection, 
cells were detached, counted (to assess cytotoxicity) and allowed to form neurospheres in 
culture medium with/without exogenous FGF2. (A) Bar chart of total cell count and (B) cell 
viability prior to neurosphere formation; (C) Bar chart showing neurosphere number and (D) 
size at 96 h after plating in neurosphere medium ± exogenous FGF2. *P < 0.05, **P < 0.01 
and ***P < 0.001 (one-way ANOVA and Bonferroni’s MCT). (E) Bar chart showing  
total cell count after dissociation of neurospheres at 144 h after plating in neurosphere  
medium ± exogenous FGF2. *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA 
and Bonferroni’s MCT). 
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In order to address if the low level of FGF2 gene delivery was of functional significance, a bioassay 
was performed utilising cells which had been magnetofected under the F = 4 Hz oscillating magnetic 
field condition only (yielded the highest transfection efficiency of 13.5%; Figure 4B). Neurosphere 
formation assays are usually conducted in the presence of exogenous EGF and FGF2, and the basis of 
this bioassay was to examine if the FGF2-GFP transgene could functionally substitute for exogenous 
FGF2, which is mitogenic for NSCs. NSCs which had been transfected with pAN-GFP or pFGF2-GFP 
could form neurospheres in standard neurosphere medium (NS-M) and in NS-M minus FGF2.  
No differences were found between the two plasmids with respect to the number of spheres formed, 
irrespective of the culture medium (Figure 5C), but differences were apparent for sphere size  
(Figure 5D). Firstly, for cells transfected with the control plasmid, larger spheres were observed in the 
presence of exogenous FGF2 than in its absence (Figure 5D), demonstrating that the FGF2 supply is 
rate-limiting for cell proliferation. While no difference was apparent between sphere size between  
pAN-GFP and pFGF2-GFP magnetofected cells cultured in NS-M containing exogenous FGF2 (i.e., 
FGF2 supply is saturating for cell proliferation), the mean diameter of spheres derived from pFGF2-GFP 
transfected monolayers was larger (by 35%) than those formed from pAN-GFP transfected cells when 
cultured in the absence of FGF2 (Figure 5D). In agreement with these findings, in medium lacking FGF2, 
there was an increase (45%) in the total number of cells recovered from neurospheres formed from 
pFGF2-GFP transfected NSCs compared with those formed from NSCs transfected with pAN-GFP 
(Figure 5E). Thus, this bioassay confirms that, despite low transfection efficiency, oscillating field 
magnetofection can deliver biologically relevant amounts of a therapeutic gene (FGF2); whether such 
levels of NSC transfection are sufficient to promote neural regeneration in vivo remains to be addressed. 
Gene expression is transient but it should be noted that regenerative events in neurological lesions are 
mediated by complex and changing profiles of expression of biomolecules in injury sites, therefore 
transient expression of repair promoting molecules by transplant populations is a desirable outcome. 
Regarding the inverse linear relationship between plasmid size and transfection efficiency, it should 
be noted that all transfections were conducted at a fixed Neuromag:DNA ratio of 3.5 µL/µg DNA, at 
which binding of DNA is maximal. The most likely explanation for this relationship therefore, is that as 
plasmid size increases, less copies of the encoded gene will be complexed with the particles. Under these 
conditions, use of plasmids of the minimum size necessary to meet the desired objective is required, in 
order to achieve maximal gene delivery. For example, the pFGF2-GFP vector encodes neomycin 
resistance and carries a GFP tag, neither of which are required for transient gene expression in vivo. 
Substitution of the gfp sequence (size ca. 710 bp) in pmaxGFP with the human FGF2 cDNA sequence 
(size 867 bp) would produce a plasmid of ca. 3.7 kb, potentially resulting in a doubling of transfection 
efficiency to ca. 25%. A similar approach should suffice to maximize delivery of genes encoding most 
neurotherapeutic growth factors whose open reading frames are typically <1.2 kb in size. Our regression 
analyses predict an upper size limit to plasmid delivery with Neuromag particles, highlighting the need 
for the design of transfection-grade MNPs with increased payload capacity, to deliver plasmids with 
large cDNA inserts or of high complexity (e.g., contain elements for regulated expression of inserts). 
This could be achieved, for example, by use of alternative polymers with higher DNA binding capacity, 
larger particles or altered particle geometries offering greater surface area for DNA binding.  
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Currently, the most popular methods to achieve gene transfer to NSCs rely on viral transduction, 
particularly based on the use of lentiviruses and retroviruses (for example, [31–34]). Viral approaches 
can be time-consuming and technically complex. Whilst recent advances in viral technology have seen 
increased safety profiles and scalable manufacture protocols introduced, viral systems still have their 
associated disadvantages in terms of safety and production scale-up [35] which impacts their suitability 
for clinical cell therapies. By contrast, oscillating field magnetofection as demonstrated here, represents 
a technically simple, quick and versatile method, which could potentially be incorporated into  
pre-existing automated systems, to transfer genetic material into target transplant cell populations. At 
non-toxic doses, MNPs outperform most other non-viral methods, notably electroporation and 
lipofection [12,25,26,36,37]. Whilst highly competitive with nucleofection, it should be noted that 
substantial loss of NSC viability can occur with the latter [25], which is undesirable for achieving optimal 
graft survival. The technical methods used require minimal cell manipulation and limited specialist 
infrastructure, implying that these can be easily adopted by other workers in the field, for a wide 
spectrum of therapeutic biomolecules, neural cell types and pathologies. Plasmid DNA is easy to produce 
in large quantities, handle and store [38] and MNPs are already in use in the clinic as contrast  
agents [39], therefore the potential for scale-up for clinical applications appears realistic.  
3. Experimental Section  
3.1. Reagents 
Cell culture reagents/plastics were from Fisher Scientific (Loughborough, UK). Human recombinant 
basic fibroblast growth factor (FGF2) and epidermal growth factor (EGF) were from Sigma (Poole, 
Dorset, UK) and R&D Systems Europe Ltd (Abingdon, UK), respectively. The magnefect-nano  
24-magnet array system was purchased from nanoTherics Ltd (Stoke-on-Trent, UK) and comprises 
horizontal arrays of NdFeB magnets (grade N42) on which 24-well culture plates are placed. Neuromag 
MNPs were from Oz Biosciences (Marseilles, France), pmaxGFP plasmid (size 3.5 kb; encodes green 
fluorescent protein [GFP]) was from Amaxa Biosciences (Cologne, Germany) and pCMV-DsRed-Express2 
plasmid (herein termed pDRE2; size 4.6 kb; encodes red fluorescent protein [RFP]) was from Clontech 
(Saint-Germain-en-Laye, France). Plasmid (pCMV6-FGF2-GFP; herein termed pFGF2-GFP) encoding 
the open reading frame of human FGF2 with a carboxy-terminal turboGFP tag (insert size 867 bp; total 
size 7.4 kb), control plasmid pCMV6-AN-GFP (herein termed pAN-GFP; size 6.6 kb) and anti-FGF2 
antibody (clone 3D9) were all from OriGene Technologies (Rockville, MD, USA). Vectashield 
mounting medium plus/minus 4´, 6-diamidino-2-phenylindole (DAPI) was from Vector Laboratories 
(Peterborough, UK). The care and use of all animals used in the production of cell cultures was in 
accordance with the Animals Scientific Procedures Act of 1986 (UK). 
3.2. NSC Culture 
NSC cultures were established from the subventricular zone of neonatal CD1 mice and routinely 
propagated as neurospheres [20]. To prepare NSC monolayers, neurospheres (passages 2–3) were 
dissociated with accutase-DNase I, cells resuspended at 3 × 105 cells/ml monolayer culture medium 
(herein termed ML-M; comprises a 1:1 mix of DMEM:F12 containing 1% N2 supplement, 50 U/mL 
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penicillin, 50 μg/mL streptomycin, 4 ng/mL heparin, 20 ng/mL FGF2 and 20 ng/mL EGF), then replated 
on polyornithine/laminin-coated, acid-washed coverslips in 24-well plates (0.4 mL suspension/well) and 
cultured at 37 °C in 95% air:5% CO2.  
3.3. MNP-Mediated Transfection of Monolayers 
3.3.1. Single Gene Delivery (Reporter and Functional Genes) 
At 24-48 h post-plating, medium was replaced with fresh ML-M (0.225 mL) before addition of 
transfection complexes. To prepare the latter, 176 ng plasmid was diluted with 75 µL DMEM:F12 (1:1) 
base medium, added to 0.62 µL Neuromag and carefully mixed, corresponding to a Neuromag:DNA 
ratio of 3.5 µL/µg (at which Neuromag: DNA binding is maximal [19]). After 20 min, the mix was added 
drop-wise to cells whilst gently swirling the plate. Controls were treated with an identical concentration 
of plasmid only. Plates were returned to the incubator, and exposed to the desired magnetic field using 
the magnefect-nano oscillating magnetic array system, with a 24-magnet array (NdFeB, grade N42; field 
strength of 421 ± 20 mT). The array moves laterally with oscillation frequency and amplitude controlled 
via a computerised motor. Oscillating fields of frequencies F = 0.5, 1, 2 and 4 Hz were applied  
(amplitude = 0.2 mm), and a static magnetic field applied by setting F to 0 Hz. Field application was for 
30 min, with incubation in the absence of a field for a further 30 min. Medium was replaced with fresh 
ML-M (0.4 mL) and cells cultured for a further 47 h. To assess functional gene delivery, the plasmid 
pFGF2-GFP was used in an identical protocol, but experiments were limited to three magnetic field 
conditions: none, static and oscillating (F = 4 Hz). Control plasmids studied in these experiments were: 
pAN-GFP (lacks the FGF2 cDNA insert) and pmaxGFP (positive control).  
3.3.2. Combinatorial Gene Delivery 
The ability of Neuromag to mediate combinatorial gene delivery was assessed using the plasmids 
pDRE2 and pmaxGFP, in a co-transfection protocol, with an applied oscillating magnetic field of  
F = 4 Hz. The protocol was similar to that for single gene delivery, except 88 ng of each plasmid was 
diluted with 75 µL base medium before adding to 0.62 µL Neuromag. Thus, the Neuromag:total DNA 
ratio was maintained at 3.5 µL/µg DNA, but the final plasmid concentration were halved. Therefore, 
single gene transfection controls using only 88 ng of each plasmid for complex formation were included. 
3.4. Assessment of Transfection Efficiency, Toxicity and Proliferative Capacity 
At 48 h post-complex addition, monolayers were washed (3X) with phosphate-buffered saline (PBS), 
fixed [4% paraformaldehyde in PBS, 20 min, room temperature (RT)] and washed again (PBS, 3X). 
Transfection efficiency was determined by fluorescence microscopy (Section 3.6). At 48 h post complex 
addition, monolayers were washed with PBS and cells detached by accutase-DNase I treatment. To 
assess cytotoxicity, cells were resuspended in ML-M (50 µL/well), mixed with trypan blue (0.2%), and 
viable cells counted using a Neubauer chamber and light microscopy; total cells per well and percentage 
cell viability were calculated. Proliferative capacity was assessed using a neurosphere formation assay: 
detached cells were resuspended at 1 × 105 cells/ml in NS-M (3:1 mix of DMEM:F12 containing 2%  
B-27 supplement, 50 U/mL penicillin, 50 μg/mL streptomycin, 4 ng/mL heparin, 20 ng/mL FGF2 and 
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20 ng/mL EGF) and plated in 24-well suspension cell plates (0.5 mL suspension/well). Cells were 
cultured for 7 days, with medium additions every 2–3 days, and intact neurospheres photographed to 
estimate sphere size, number and proportions of transfected spheres (Section 3.6). To assess long-term 
gene expression, neurospheres were dissociated (accutase-DNase I), replated at weekly intervals and 
scored for the proportions of labelled spheres and for the extent of transfection. A neurosphere assay 
was also used to assess functional effects of FGF2 gene delivery on NSCs, since FGF2 is mitogenic for 
NSCs. The standard neurosphere medium contains exogenous FGF2, which may mask mitogenic effects 
of transgenic FGF2, therefore neurospheres were formed in standard NS-M and in NS-M minus FGF2. 
Sphere number and size were determined at 96 h, and neurospheres were dissociated at 144 h for  
cell counting.  
3.5. Immunoblotting 
Transfected NSCs were detached (accutase:DNase I), washed twice with ice-cold PBS, then protein 
extracted with RIPA buffer containing 1% (v/v) protease inhibitor cocktail (80 µL buffer/106 cells) for 
30 min on ice with periodic vortexing. Samples (15 µL) were denatured with an equal volume of 2X 
Laemmli buffer by boiling (10 min), centrifuged (10,000 g; 10 min; 4 °C) and supernatants 
electrophoresed (12% Tris-HCl Ready gels); protein was electrotransferred in Towbin buffer to 
Immobilon-P membrane. Immunodetection was by the standard protocol supplied with the ECL Western 
blotting detection reagent, using 5% non-fat dry milk as blocker. Blots were probed with FGF2 primary 
antibody at 1:1000 dilution, and secondary antibody at 1:1000 dilution, stripped then reprobed with  
β-actin (loading control) primary antibody at 1:10000 dilution and secondary antibody at 1:1000 dilution. 
All blots were exposed to Hyperfilm-ECL (preflashed to 0.05 optical density units above background), 
and images captured using a Bio-Rad GS-800 scanner. 
3.6. Microscopy and Image Analysis 
Fluorescence microscopy of monolayers and tissue slices was performed using an AxioScope A1 
microscope equipped with an Axio Cam ICc1 digital camera and AxioVision software (release 4.7.1, 
Carl Zeiss MicroImaging GmbH, Goettingen, Germany). Phase-contrast and fluorescence microscopy 
of live neurospheres was performed using a Leica DM IL LED inverted microscope equipped with a 
FC420C digital camera and Leica Applications Suite software version 3.4.0 (Leica Microsystems, Wetzlar, 
Germany). Images were merged using Adobe Photoshop CS3 (version 10.0.1) prior to quantification. 
The efficiency of single gene transfection was determined from double merges of DAPI and GFP/RFP 
as appropriate; a minimum of 200 cells at ×200 magnification were scored. The efficiency of 
combinatorial gene delivery was assessed from triple-merges of DAPI, GFP and RFP images;  
≥50 transfected cells at ×200 magnification were scored. Sphere size/number was determined from  
phase-contrast micrographs and the average sphere size/number per culture determined. Proportions of 
transfected neurospheres were determined from double-merges of phase-contrast and GFP images;  
a minimum of three microscopic fields at ×100 magnification (≥50 neurospheres in total) were assessed. 
Neurospheres were further scored for the extent of transfection, based on the proportion of cells within 
a sphere demonstrating GFP expression; categories were “low” (≤10%), “moderate” (11%–50%), and 
“high” (≥51%).  
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3.7. Statistical Analysis 
Data are expressed as mean ± SEM. A paired Student’s t-test was used to compare transfection 
efficiencies for pmaxGFP and pDRE2 controls in the combinatorial gene delivery experiment; all other 
data were analyzed by a one-way ANOVA and Bonferroni’s multiple comparison test (MCT). Statistical 
analyses were performed using GraphPad Prism 4 for Windows software (version 4.03). The numbers 
of experiments (n) relate to the number of NSC cultures, each generated from a different litter. 
4. Conclusions  
Oscillating magnetic fields utilized with MNPs offer significant advantages for safe and efficient 
transfection of NSCs propagated as monolayers (in contrast to NSC propagation in the suspension 
neurosphere format where transfection levels are considerably lower). The methodology can be used 
both for delivery of multiple and neurotherapeutic genes, highlighting the relevance of the approach to 
genetically augmenting the repair capacity of transplant populations to regenerative neurology.  
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